Evidence-based guideline update

Treatment of essential tremor: Report of the Quality Standards Subcommittee of the American Academy of Neurology

T. A. Zesiewicz, R. J. Elble, E. D. Louis, G. S. Gronseth, W. G. Ondo, R. B. Dewey, M. S. Okun, K. L. Sullivan, W. J. Weiner

Research output: Contribution to journalArticle

149 Citations (Scopus)

Abstract

Background: This evidence-based guideline is an update of the 2005 American Academy of Neurology practice parameter on the treatment of essential tremor (ET). Methods: A literature review using MEDLINE, EMBASE, Science Citation Index, and CINAHL was performed to identify clinical trials in patients with ET published between 2004 and April 2010. Results and Recommendations: Conclusions and recommendations for the use of propranolol, primidone (Level A, established as effective); alprazolam, atenolol, gabapentin (monotherapy), sotalol, topiramate (Level B, probably effective); nadolol, nimodipine, clonazepam, botulinum toxin A, deep brain stimulation, thalamotomy (Level C, possibly effective); and gamma knife thalamotomy (Level U, insufficient evidence) are unchanged from the previous guideline. Changes to conclusions and recommendations from the previous guideline include the following: 1) levetiracetam and 3,4-diaminopyridine probably do not reduce limb tremor in ET and should not be considered (Level B); 2) flunarizine possibly has no effect in treating limb tremor in ET and may not be considered (Level C); and 3) there is insufficient evidence to support or refute the use of pregabalin, zonisamide, or clozapine as treatment for ET (Level U).

Original languageEnglish (US)
Pages (from-to)1752-1755
Number of pages4
JournalNeurology
Volume77
Issue number19
DOIs
StatePublished - Nov 8 2011

Fingerprint

Essential Tremor
Guidelines
zonisamide
etiracetam
Tremor
Nadolol
Primidone
Flunarizine
Alprazolam
Sotalol
Therapeutics
Clonazepam
Nimodipine
Type A Botulinum Toxins
Deep Brain Stimulation
Atenolol
Clozapine
Propranolol
MEDLINE
Clinical Trials

ASJC Scopus subject areas

  • Clinical Neurology
  • Arts and Humanities (miscellaneous)

Cite this

Evidence-based guideline update : Treatment of essential tremor: Report of the Quality Standards Subcommittee of the American Academy of Neurology. / Zesiewicz, T. A.; Elble, R. J.; Louis, E. D.; Gronseth, G. S.; Ondo, W. G.; Dewey, R. B.; Okun, M. S.; Sullivan, K. L.; Weiner, W. J.

In: Neurology, Vol. 77, No. 19, 08.11.2011, p. 1752-1755.

Research output: Contribution to journalArticle

Zesiewicz, TA, Elble, RJ, Louis, ED, Gronseth, GS, Ondo, WG, Dewey, RB, Okun, MS, Sullivan, KL & Weiner, WJ 2011, 'Evidence-based guideline update: Treatment of essential tremor: Report of the Quality Standards Subcommittee of the American Academy of Neurology', Neurology, vol. 77, no. 19, pp. 1752-1755. https://doi.org/10.1212/WNL.0b013e318236f0fd
Zesiewicz, T. A. ; Elble, R. J. ; Louis, E. D. ; Gronseth, G. S. ; Ondo, W. G. ; Dewey, R. B. ; Okun, M. S. ; Sullivan, K. L. ; Weiner, W. J. / Evidence-based guideline update : Treatment of essential tremor: Report of the Quality Standards Subcommittee of the American Academy of Neurology. In: Neurology. 2011 ; Vol. 77, No. 19. pp. 1752-1755.
@article{bed3f96998a54b51a8ef33afa2680c44,
title = "Evidence-based guideline update: Treatment of essential tremor: Report of the Quality Standards Subcommittee of the American Academy of Neurology",
abstract = "Background: This evidence-based guideline is an update of the 2005 American Academy of Neurology practice parameter on the treatment of essential tremor (ET). Methods: A literature review using MEDLINE, EMBASE, Science Citation Index, and CINAHL was performed to identify clinical trials in patients with ET published between 2004 and April 2010. Results and Recommendations: Conclusions and recommendations for the use of propranolol, primidone (Level A, established as effective); alprazolam, atenolol, gabapentin (monotherapy), sotalol, topiramate (Level B, probably effective); nadolol, nimodipine, clonazepam, botulinum toxin A, deep brain stimulation, thalamotomy (Level C, possibly effective); and gamma knife thalamotomy (Level U, insufficient evidence) are unchanged from the previous guideline. Changes to conclusions and recommendations from the previous guideline include the following: 1) levetiracetam and 3,4-diaminopyridine probably do not reduce limb tremor in ET and should not be considered (Level B); 2) flunarizine possibly has no effect in treating limb tremor in ET and may not be considered (Level C); and 3) there is insufficient evidence to support or refute the use of pregabalin, zonisamide, or clozapine as treatment for ET (Level U).",
author = "Zesiewicz, {T. A.} and Elble, {R. J.} and Louis, {E. D.} and Gronseth, {G. S.} and Ondo, {W. G.} and Dewey, {R. B.} and Okun, {M. S.} and Sullivan, {K. L.} and Weiner, {W. J.}",
year = "2011",
month = "11",
day = "8",
doi = "10.1212/WNL.0b013e318236f0fd",
language = "English (US)",
volume = "77",
pages = "1752--1755",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "19",

}

TY - JOUR

T1 - Evidence-based guideline update

T2 - Treatment of essential tremor: Report of the Quality Standards Subcommittee of the American Academy of Neurology

AU - Zesiewicz, T. A.

AU - Elble, R. J.

AU - Louis, E. D.

AU - Gronseth, G. S.

AU - Ondo, W. G.

AU - Dewey, R. B.

AU - Okun, M. S.

AU - Sullivan, K. L.

AU - Weiner, W. J.

PY - 2011/11/8

Y1 - 2011/11/8

N2 - Background: This evidence-based guideline is an update of the 2005 American Academy of Neurology practice parameter on the treatment of essential tremor (ET). Methods: A literature review using MEDLINE, EMBASE, Science Citation Index, and CINAHL was performed to identify clinical trials in patients with ET published between 2004 and April 2010. Results and Recommendations: Conclusions and recommendations for the use of propranolol, primidone (Level A, established as effective); alprazolam, atenolol, gabapentin (monotherapy), sotalol, topiramate (Level B, probably effective); nadolol, nimodipine, clonazepam, botulinum toxin A, deep brain stimulation, thalamotomy (Level C, possibly effective); and gamma knife thalamotomy (Level U, insufficient evidence) are unchanged from the previous guideline. Changes to conclusions and recommendations from the previous guideline include the following: 1) levetiracetam and 3,4-diaminopyridine probably do not reduce limb tremor in ET and should not be considered (Level B); 2) flunarizine possibly has no effect in treating limb tremor in ET and may not be considered (Level C); and 3) there is insufficient evidence to support or refute the use of pregabalin, zonisamide, or clozapine as treatment for ET (Level U).

AB - Background: This evidence-based guideline is an update of the 2005 American Academy of Neurology practice parameter on the treatment of essential tremor (ET). Methods: A literature review using MEDLINE, EMBASE, Science Citation Index, and CINAHL was performed to identify clinical trials in patients with ET published between 2004 and April 2010. Results and Recommendations: Conclusions and recommendations for the use of propranolol, primidone (Level A, established as effective); alprazolam, atenolol, gabapentin (monotherapy), sotalol, topiramate (Level B, probably effective); nadolol, nimodipine, clonazepam, botulinum toxin A, deep brain stimulation, thalamotomy (Level C, possibly effective); and gamma knife thalamotomy (Level U, insufficient evidence) are unchanged from the previous guideline. Changes to conclusions and recommendations from the previous guideline include the following: 1) levetiracetam and 3,4-diaminopyridine probably do not reduce limb tremor in ET and should not be considered (Level B); 2) flunarizine possibly has no effect in treating limb tremor in ET and may not be considered (Level C); and 3) there is insufficient evidence to support or refute the use of pregabalin, zonisamide, or clozapine as treatment for ET (Level U).

UR - http://www.scopus.com/inward/record.url?scp=82955243943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82955243943&partnerID=8YFLogxK

U2 - 10.1212/WNL.0b013e318236f0fd

DO - 10.1212/WNL.0b013e318236f0fd

M3 - Article

VL - 77

SP - 1752

EP - 1755

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 19

ER -